| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 629 companies in the Biotechnology industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | IMVT Immunovant, Inc. | Girao Tiago | Chief Financial Officer | Sell | 10,000 | $38.46 | $384,600.00 | -3.9% | - | - | |
| Jun 26, 2026 | IMVT Immunovant, Inc. | Van Tuyl Christopher | Chief Legal Officer | Sell | 17,824 | $38.31 | $682,886.90 | -4.7% | - | - | |
| Jun 26, 2026 | PCVX Vaxcyte, Inc. | Pickering Grant50 | Chief Executive Officer | Sell | 24,237 | $55.22 | $1,338,269.91 | -1.1% | - | - | |
| Jun 26, 2026 | IMVT Immunovant, Inc. | Pande Atul74 | Director | Sell | 1,500 | $38.01 | $57,015.00 | -1.3% | - | - | |
| Jun 26, 2026 | IMVT Immunovant, Inc. | Gloria Melanie | Chief Operating Officer | Sell | 17,714 | $38.31 | $678,604.34 | -3.8% | - | - | |
| Jun 26, 2026 | IMVT Immunovant, Inc. | Stout Jay S63 | Chief Technology Officer | Sell | 40,000 | $38.31 | $1,532,309.48 | -8.5% | - | - | |
| Jun 26, 2026 | KYMR Kymera Therapeutics, Inc. | Bvf Partners L P/il59 | Director, See Remarks And Footnotes | Sell | 1,630,658 | $106.50 | $173,665,077.00 | -29.6% | - | - | |
| Jun 26, 2026 | CVKD Cadrenal Therapeutics, Inc. | Pham Quang X49 | Chairman, CEO And Interim CFO | Sell | 11,156 | $3.04 | $33,919.45 | -4.8% | - | - | |
| Jun 26, 2026 | SNSE Sensei Biotherapeutics, Inc. | Stephenson Brian C | Chief Financial Officer | Buy | 15,641 | $25.65 | $401,268.52 | +7.6% | - | - | |
| Jun 26, 2026 | IONS Ionis Pharmaceuticals, Inc. | Monia Brett P60 | Chief Executive Officer | Sell | 85,637 | $79.70 | $6,825,523.71 | -10.4% | - | - | |
| Jun 25, 2026 | NRIX Nurix Therapeutics, Inc. | Ring Christine77 | Chief Legal Officer | Sell | 28,935 | $20.06 | $580,505.54 | -68.1% | - | - | |
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc. | Roberts Brandi | Chief Financial Officer | Sell | 3,013 | $45.03 | $135,675.39 | -1.4% | - | - | |
| Jun 25, 2026 | SYRE Spyre Therapeutics, Inc. | Burrows Scott L74 | Chief Financial Officer | Sell | 15,000 | $87.13 | $1,307,000.00 | -6.8% | - | - | |
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc. | Wiley Matthew T.82 | Chief Commercial Officer | Sell | 2,867 | $45.03 | $129,101.01 | -1.6% | - | - | |
| Jun 25, 2026 | KYMR Kymera Therapeutics, Inc. | Goodman Noah | Chief Business Officer | Sell | 5,000 | $114.00 | $570,000.00 | -4.6% | - | - | |
| Jun 25, 2026 | KRYS Krystal Biotech, Inc. | Thomas John Charles | EVP, General Counsel | Sell | 1,000 | $347.27 | $347,270.00 | -100% | - | - | |
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc. | Barrow Robert | Chief Executive Officer | Sell | 29,208 | $45.03 | $1,315,236.24 | -2.6% | - | - | |
| Jun 25, 2026 | IONS Ionis Pharmaceuticals, Inc. | Swayze Eric63 | EVP Research | Sell | 10,602 | $79.18 | $839,491.80 | -32.8% | - | - | |
| Jun 25, 2026 | NRIX Nurix Therapeutics, Inc. | Hansen Gwenn73 | Chief Scientific Officer | Sell | 5,394 | $20.00 | $107,880.00 | -4.5% | - | - | |
| Jun 25, 2026 | ILMN Illumina, Inc. | Davies Scott M | Chief Legal Officer | Sell | 615 | $180.00 | $110,700.00 | -2.9% | - | - | |
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc. | Karlin Daniel | Chief Medical Officer | Sell | 10,035 | $45.03 | $451,876.05 | -2.0% | - | - | |
| Jun 25, 2026 | DFTX Definium Therapeutics, Inc. | Sullivan Mark | Chief Legal Officer | Sell | 13,008 | $45.03 | $585,750.24 | -3.9% | - | - | |
| Jun 25, 2026 | PTCT Ptc Therapeutics, Inc. | Almstead Neil Gregory52 | Chief Technical Ops Officer | Sell | 26,283 | $85.78 | $2,254,463.35 | -5.7% | - | - | |
| Jun 25, 2026 | KYMR Kymera Therapeutics, Inc. | Booth Bruce70 | Director | Sell | 285,684 | $121.86 | $34,812,908.93 | -0.7% | - | - | |
| Jun 25, 2026 | KYMR Kymera Therapeutics, Inc. | Booth Bruce70 | Director | Sell | 398,765 | $110.31 | $43,987,354.76 | -0.7% | - | - |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.